Cancer Biology

Discussions of New Developments and Updates

Skip to content

Home
About
Topics
SHU Department of Biology

Tag Archives: NewLink

Immunotherapy of Cancer: Roche & NewLink $1 Billion Deal for IDO Inhibition

Roche (Genentech) entered into a $1 billion deal with NewLink Genetics, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor. Continue reading →

This entry was posted in Checkpoint Inhibitors, IDO, Uncategorized and tagged checkpoint inhibitors, IDO inhibition, NewLink, Roche on October 26, 2014 by Joseph Gulfo.

Search for:

This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]

Proudly powered by WordPress

Pin It on Pinterest